Biomerica, Inc. BMRA

Fiscal 2026 fourth quarter net sales increased approximately 17% compared to the fourth quarter of fiscal 2025Full-year net loss improved by approximately 24% to approximately $3.8 millionInFoods IBS update: 100% of all initial valid claims processed to date have been paid at the full CMS payment rate of $300Research and development expenses decreased 23% as key programs transition toward commercializationSubsequent to fiscal year-end: completed a $2.23 million financing with no warrants or disc

Financing priced at $1.60 with no warrants or discountB. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica’s Board of Directors participated in the financingProceeds expected to strengthen the Company's balance sheet and fund operations and support the Board's ongoing evaluation of potential strategic opportunities, including partnerships and business combinations IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMR